


A cluster
for innovative
therapies
and advanced
technologies
in healthcare



INNOVATION
PARTNERSHIP
NETWORK

Healthcare and life science in the Paris region: the dynamism of a European leader

The Paris region has committed to leveraging excellence and innovation by federating its dynamism and skills in life science within the Medicen Paris Region cluster.

The Paris Region, 1st European region*

- **11.6 million** inhabitants*
- **Europe's most powerful region** in terms of GDP: 553 billion euros*
- **The world's second most dense cluster** of multinational businesses*
- **137,300** people working in R&D**
- **3.1%** of GDP spent on R&D**
- **182** patents per million inhabitants**

* 2008 data

** Source: Eurostat 2010 (2006 data)

The Paris region: the European leader in life science research and business*

- **50%** of France's biotechnology companies
- **40%** of France's academic research
- **9** universities, covering all scientific and technical disciplines and about **20** "Grandes Écoles"
- Prestigious, world-renowned **institutions**: Pasteur, Curie, Gustave Roussy, etc
- **More than 300** public research centres
- **AP-HP** : Europe's largest hospital network (the Paris Public Hospitals Group)
- Some of the **international leaders**

*Source: The Paris Region Economic Development Agency (2008 data)

Medicen Paris Region

Our mission

To maintain and reinforce the Paris region as Europe's leading industrial center for **diagnostic & therapeutic innovation and health technologies**.

Three core activities

- 1** Catalyzing economic growth and employment in thriving markets by successfully interfacing start-ups/SMEs, multinationals, academic laboratories, hospitals, training organizations and healthcare providers and promoting innovative technology transfer.
- 2** Reinforcing the international competitiveness of the healthcare and medtech sector by stimulating the region's innovative capacity.
- 3** Boosting the Paris region's attractiveness and dynamism.



Medicen Paris Region's strategic orientations for R&D

Medicen's R&D strategy is based on the broad range of in-depth skills available in the Paris region. The cluster stimulates academic and clinical stakeholders, meets the needs of its member companies and helps to develop the region's economic tissue by growing and capitalizing on the rich technology offering from its start-ups, SMEs and CROs.

Medicen Paris Region has selected 3 R&D themes

THEME 1 Translational Medicine (clinical research, medical imaging) to promote access to medical innovation.

THEME 2 Biological tools for industrial use and biotherapeutic products for better diagnosis, treatment and prognosis.

THEME 3 Digital biology, bioinformatics, Integrative Systems Biology and modeling/e-healthcare/the brain-machine interface, in order to better understand, model and simulate disease.


3 fields with significant unmet diagnostic and therapeutic needs

FIELD 1 Cancer.


FIELD 2 Neurodegenerative, sensory and psychiatric diseases.

FIELD 3 Infectious diseases.

The heart of Medicen Paris Region's strategy: catalyzing **innovation transfer** from research providers into the industrial sector and reducing the time to market for therapeutic and/or technological innovations.




A CROSS-DISCIPLINARY, CROSS-SECTOR APPROACH



A dynamic cluster:

helping to boost the Paris region's competitiveness, international profile and attractiveness for companies, R&D activities, talented individuals and investments.



The Paris region is home to many **innovation-focused business parks and first-and second-stage company incubators.**

The Paris region bioparks

- 1. Biocitech**
(www.biocitech.com)
 - 8 hectares of real estate
 - 28,500 square meters of office and lab space
 - 24 companies, including 8 start-ups
- 2. Paris Biotech Santé**
(www.parisbiotech.org)
- 3. Cancer Campus**
(www.cancer-campus.com)
- 4. Genopole®**
(www.genopole.fr)
 - 21 academic research labs, including the CEA Genomics Institute (which houses the French national sequencing and genotyping centers)
 - 70 life science companies
 - 18 shared-access technical facilities and technology platforms
 - 87,298 square meters of lab and office space

A company network which covers the entire healthcare market, with big pharma research centers and corporate headquarters and a hundred or so market-leading SMEs.

The French pharmaceutical market*

- Europe's top exporter
- Ranked 5th in the world for exports
- The world's 4th largest market and number 2 in Europe
- 220 production sites
- An annual R&D spend of **4 billion euros**, i.e. 11.3% of turnover

**Source: The Paris Region Economic Development Agency (2008 data)*

Leading multinationals are headquartered or located in the Paris region:

Bio-Rad, CIS bio international, GE Medical Systems, GlaxoSmithKline, Guerbet, Innothera Services, Servier, LFB, Philips Medical Systems France, sanofi-aventis, IPSEN, Siemens Medical Solutions France.

The Paris region accounts for 40% of the country's **academic research**; Medicen Paris Region is a portal for accessing centers of excellence.

The cluster's academic members

American Hospital of Paris
AP-HP
Cancer Campus
Cancéropôle Île-de-France
CEA/DSV
CNRS
École Centrale de Paris
École des Mines Paris (ENSMP)/ARMINES
ENS Cachan
ESME Sudria
Généthon
Genopole®
INRIA
Inserm
Institut Curie
Institut de cancérologie Gustave Roussy
Institut Pasteur
Institut Sup'Biotech
Soleil Synchrotron
Université de Cergy-Pontoise
Université de Versailles St Quentin-en-Yvelines
Université d'Evry-Val-d'Essonne
Université Paris 5 - René Descartes
Université Pierre et Marie Curie - UPMC
Université Paris Diderot - Paris 7
Université Paris-Sud 11
Université Paris 12 Paris Est Créteil
Université Paris-Nord 13

The R&D projects

Medicen Paris Region's objective is to **catalyze the emergence of scientifically, technically and economically validated collaborative R&D projects** between public-and private-sector partners. Project accreditation by the cluster opens the door to several attractive or additional sources of public funding.

Since the cluster was created in 2005*, **51** R&D collaborative projects have been accredited and **42** of these have been funded by the French State and local authorities. Furthermore, the French National Research Agency has funded **110** of the **227** individual projects accredited by the cluster since its initiation, under specific calls for proposals.

**October 2010 data.*

Medicen Paris Region also supports the development of **several infrastructure projects** to spark the development of world-class R&D projects which are in line with the cluster's objectives. Eurocord (umbilical cord blood samples and transplantation) and the Vision Institute (the only research center in Europe dedicated solely to eye diseases) are two of these.

As part of the first call for proposals on innovation platforms, **2** of **4** projects accredited by the cluster in 2009 have already been funded by the French State, the Île-de-France Regional Council, other local councils, the Caisse des Dépôts state-owned savings bank and/or the FEDER. Funding is currently being put together for a **3rd** project. These projects cover the following areas: radiotherapy, biological resources and the production & dissemination of human cell-based tools. In 2010, the cluster supported **5** candidate innovation platforms.



The cluster's European and international strategy



A European ambition

Medicen Paris Region is involved in a major European project: **Advanced Bioclusters for Europe** seeks to reinforce collaborations between 13 European clusters and their members companies and provide high-quality support services to biotech firms. The ultimate goal is to develop and apply good practice and help cluster SMEs to grow their international business.

A high-quality business and R&D environment

The Paris region enables access to all types of partners for all R&D phases and all preclinical and clinical disciplines but above all offers a range of business support tools for life science and medtech companies wishing to relocate to the region. The French research tax credit scheme is the most attractive in Europe.

Members and funding partners*

- A**BCell-Bio
- AIR SÛR
- Agence de Développement du Val-de-Marne
- AgiLab
- Alfact Innovation
- Alpha chimica
- Amplitude Technologies
- American Hospital of Paris
- Anaconda Pharma
- ANR
- AnyGenes
- APCIS
- AP-HP
- Applied Biosystems
- Ariana Pharma
- ART
- ARTM-Eurocord
- Aterovax
- Aureus Pharma
- B**ALT Extrusion
- BioAlliance Pharma
- Biocitech
- Biocortech
- Agdia Biofords
- Biométhodes
- Bio-Modeling Systems
- Biophytis
- BioProtein Technologies
- BioQuanta
- Bio-Rad
- Biorebus
- BIOS Chemicals
- Biospace Lab
- Biospace Med
- Biosystems International
- BiotechInfo Diffusion
- Biotrial
- C**ARThéra
- Cancéropôle Île-de-France
- Cancer Campus
- Cardinal Systems
- CEA
- CEDIB
- CEEVO
- Cellectis
- CellVir
- CEMO
- Centaure Metrix
- Centre CAP Phase I/II
- CHEM-X-INFINITY
- Chiesi
- CIRA
- CIS bio international
- CNRS
- Comité Adebitech
- Communauté d'agglomération Evry Centre Essonne
- Conseil général 78
- Conseil général 91
- Conseil général 92
- Conseil général 93
- Conseil général 94
- Conseil général 95
- Conseil Régional Île-de-France
- CyToCap
- D**aVolterra
- DBV Technologies
- Direct Medica
- DIVERCHIM
- DGCIS
- DNA Therapeutics
- Dosisoft
- DIRECCTE Île-de-France
- Drugabilis
- E**(ye)BRAIN
- Echosens
- École Centrale de Paris
- École des Mines Paris (ENSM) / ARMINES
- E-Medicis
- Endotis Pharma
- ENS Cachan
- Epixis
- ESI Group
- ESME Sudria
- Ethypharm
- F**AB Pharma
- Fluigent
- Futurs Health Products
- G**1J Île-de-France
- Galapagos
- GE Medical Systems
- Généthon
- Genewave
- Genopole@
- Genoptics
- GenoSplice technology
- Global Imagine Online
- GlaxoSmithKline
- Guerbet
- H**armonic Pharma
- Harrison Clinical Research
- Helios Biosciences
- Hybrigenics
- I**mmunoClin
- Immutep
- IMSTAR
- IMT
- InnaVirVax
- INNOTHERA SERVICES
- INRIA
- Inserm
- Institut Curie
- Institut de cancérologie Gustave Roussy
- Institut de Myologie
- Institut Pasteur
- Institut Sup'Biotech
- Innovaction
- IntegraGen
- Ipsen
- K**ayentis
- Keocyt
- L**FB
- LK2
- LLTech
- M**APREG
- Mauna Kea Technologies
- MAYOLY SPINDLER
- MEDIT
- Metabrain Research
- MicroBioChipS
- Mitologics
- Moleac
- Myosix
- N**ANOBACTERIE
- Noesis
- NOVACYT
- Novagali Pharma
- Novoxel
- O**ligovax
- OPIA Technologies
- Oncodesign
- Only for children pharmaceuticals
- Ophthalmia
- Oroxcell
- Oséo
- Osseomatrix
- OTR3
- P**aris Biotech Santé
- Pharmaleads
- Pharnext
- Pherecydes Pharma
- Philips Systèmes Médicaux France
- Physip
- PrimaDiag
- Q**uinten
- R**oowin
- S**anofi-aventis
- ScarCell Therapeutics
- SeleXel
- SenoCAD Research
- Sepal Pharma
- Servier
- (Institut de Recherches Internationales Servier)
- Siemens Medical Solutions France
- Sis'N Com
- SOLEIL Synchrotron
- SPI-Bio
- Statlife
- STERIS
- T**ebu-bio
- TEKNEO
- TRIBVN
- U**niversité de Cergy-Pontoise
- Université de Versailles St Quentin-en-Yvelines
- Université d'Evry-Val-d'Essonne
- Université Paris 5 - René Descartes
- Université Pierre et Marie Curie - UPMC
- Université Paris Diderot-Paris 7
- Université Paris-Sud 11
- Université Paris 12
- Paris Est Créteil
- Université Paris-Nord 13
- V**axconsulting
- VAXON Biotech
- Ville de Paris
- VFS-Bio
- VigiCell
- Voisin Consulting
- W**atchFrog
- Wittycell
- X**enTech

*October 2010

Medicen Paris Region,
one of the Europe's largest Life
Science and Healthcare
gathering and the right **gateway**
to access european biotechnologies
and markets.

Contact

Medicen Paris Region
6 rue Alexandre Cabanel
75015 Paris
Tél : +33 (1) 44 49 30 00
medicen@medicen.org

www.medicen.org



Cluster and project funding partners

